AbbVie Inc.
- ABBV
- NYSE
- Drug manufacturers
- Biopharmaceuticals (Immunology/Inflammation)
- Drug Discovery & Manufacturing
$285.42
Today +0.71%Quote Oct 16, 2026, 08:00 PM UTC
+8.11%over the last month
Max drawdown −2.4%From 1-month high 0.0%3 months +12.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$504.37B
Quote Oct 16
Next earnings
Oct 30
Expected, not confirmed
Analyst target
$292.21
+2.4% from here
Floor
$282.62
1.0% below price
Where the price sits
44 analysts
Analyst range, low to high
$235.00$320.00
- Price $285.42
- Resistance $288.76
- Consensus $292.21
The price is just above its floor and right under resistance. Analysts' average target sits about 2% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ABBVPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $16.99B
- SKYRIZI$5.50B32.4%
- RINVOQ$2.52B14.9%
- Other Products$1.11B6.5%
- Vraylar$1.07B6.3%
- Botox Therapeutic$1.04B6.1%
- VENCLEXTA$771.0M4.5%
- H U M I R A$756.0M4.4%
- Botox Cosmetic$728.0M4.3%
- Imbruvica$532.0M3.1%
- Ubrelvy$392.0M2.3%
- Qulipta$350.0M2.1%
- Other Aesthetics$309.0M1.8%
- Other$952.0M5.6%
- Other / not reported$948.0M5.6%
Industry
Drug manufacturers
Employees
57,000
Founded
2012